Background Available treatments for hepatitis B e antigen (HBeAg)–negative chronic hepatitis
B are associated with poor sustained responses. As a result, nucleoside and nucleotide …

We investigated the relationship between hepatitis B virus surface antigen (HBsAg) serum
level decline and posttreatment response in patients with hepatitis B e antigen (HBeAg)‐…

Background and Aim: Decisions on public health issues are dependent on reliable
epidemiological data. A comprehensive review of the literature was used to gather country‐specific …

Background & Aims: Lamivudine treatment is associated with frequent development of resistant
hepatitis B virus (HBV) and loss of treatment benefit. In preclinical and phase II studies, …

Background Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in
the most severe form of viral hepatitis. There is no currently approved treatment. We …

Background & Aims Risk scores for hepatocellular carcinoma (HCC) developed in Asians
offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This …

BACKGROUND & AIMS: Patients with hepatitis B e antigen (HBeAg)–negative chronic
hepatitis B treated with peginterferon alfa-2a with or without lamivudine achieve significantly …

Objective: To determine whether endogenous opioids contribute to the pruritus of cholestasis
by studying the effect of the opiate antagonist naloxone on the perception of pruritus and …

Objective: To evaluate ribavirin, an oral antiviral agent, as therapy for chronic hepatitis C.
Design: Randomized, double-blind, placebo-controlled study. Setting: Clinical Center of the …

Acute clinical deterioration in patients with chronic liver disease may result in multisystem
organ failure and is associated with significant morbidity and mortality, with per-patient costs …